We therefore suggest that combination therapy with a HMA and a PD-1 pathway inhibitor in the treatment of higher-risk MDS will release this “brake” on the tumor-specific T cells, potentially enhancing their function. Here, PDCD1 is linked to myelodysplastic syndrome.